UK Markets close in 1 hr

Orchard Therapeutics plc (ORTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
0.9769-0.0331 (-3.28%)
As of 04:00PM EST. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 1.11
52-week change 3N/A
S&P500 52-week change 3N/A
52-week high 39.0800
52-week low 30.8800
50-day moving average 31.3180
200-day moving average 33.1176

Share statistics

Avg vol (3-month) 31.01M
Avg vol (10-day) 3687.97k
Shares outstanding 5125.5M
Implied shares outstanding 6N/A
Float 879.62M
% held by insiders 10.12%
% held by institutions 160.01%
Shares short (14 Dec 2021) 41.71M
Short ratio (14 Dec 2021) 42.12
Short % of float (14 Dec 2021) 4N/A
Short % of shares outstanding (14 Dec 2021) 41.36%
Shares short (prior month 14 Nov 2021) 45.64M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)29 Sept 2021


Profit margin 0.00%
Operating margin (ttm)-11,811.33%

Management effectiveness

Return on assets (ttm)-26.91%
Return on equity (ttm)-63.28%

Income statement

Revenue (ttm)1.19M
Revenue per share (ttm)0.01
Quarterly revenue growth (yoy)-40.30%
Gross profit (ttm)1.74M
EBITDA -138.69M
Net income avi to common (ttm)-141.86M
Diluted EPS (ttm)-1.2120
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)254.14M
Total cash per share (mrq)2.03
Total debt (mrq)60.84M
Total debt/equity (mrq)25.22
Current ratio (mrq)6.59
Book value per share (mrq)1.93

Cash flow statement

Operating cash flow (ttm)-103.53M
Levered free cash flow (ttm)-63.97M